Loading organizations...
§ Private Profile · Durham, NC, USA
A clinical-stage biopharmaceutical company developing personalized immunotherapies for cancer and infectious diseases using Arcelis.
Argos Therapeutics was a Durham, North Carolina-based clinical-stage biopharmaceutical company that developed fully personalized immunotherapies for cancer and infectious diseases using its proprietary Arcelis technology platform. The organization focused primarily on immuno-oncology treatments, specifically targeting metastatic renal cell carcinoma and HIV by utilizing a patient's own dendritic cells to activate disease-specific immune responses. Before ceasing independent operations, the enterprise scaled to approximately 130 employees and raised over $250 million in total funding, which included a $45 million initial public offering in 2014. The biotechnology firm secured financial backing from notable investors such as Forbion Capital Partners and Pharmstandard before its assets were ultimately acquired by South Korean biotech companies SCM Lifescience and Genexine following a 2018 bankruptcy filing. Originally established as Merix Bioscience, the company was founded in 1997 by Nobel Laureate Ralph Steinman and Charles Nicolette.
Argos Therapeutics has raised $86.5M across 4 funding rounds.
Argos Therapeutics has raised $86.5M in total across 4 funding rounds.
Argos Therapeutics has raised $86.5M across 4 funding rounds. Most recently, it raised $1.5M Other Equity in January 2018.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Jan 10, 2018 | $1.5M Venture Round | Lummy | — | Announced |
| Nov 20, 2013 | $17.5M Series E Plus | — | Aurora Funds, Forbion, Green Cross Holdings, Intersouth Partners, Lumira Ventures, Morningside, Pharmstandard International, TVM Capital | Announced |
| Aug 28, 2013 | $42.5M Series E | Alexandr Shuster | Aurora Funds, Forbion, Green Cross Holdings, Intersouth Partners, Lumira Ventures, Morningside, TVM Capital | Announced |
| Apr 24, 2012 | $25M Series D | Forbion | Aurora Funds, Intersouth Partners, Lumira Ventures, Morningside, TVM Capital | Announced |
Argos Therapeutics has raised $86.5M in total across 4 funding rounds.
Argos Therapeutics's investors include Lummy, Aurora Funds, Forbion, Green Cross Holdings, Intersouth Partners, Lumira Ventures, Morningside, Pharmstandard International, TVM Capital, Alexandr Shuster.